Business Context and Reporting Period
This Form 8-K is a current report filed by BioSig Technologies, Inc. (not Streamex Corp.) on September 9, 2020. The registrant is a Delaware corporation with its principal executive offices in Westport, Connecticut. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a corporate event rather than a periodic financial statement.
Material Changes
No material financial changes versus a prior period are reported in this document. The primary event is the announcement of an upcoming investor call by the Company's majority-owned subsidiary, ViralClear Pharmaceuticals, Inc.
Guidance, Outlook, and Management Commentary
- Upcoming Event: ViralClear will host a call on September 22, 2020, at 11:00 AM Eastern Time.
- Topic: Discussion of a Phase 2 clinical trial evaluating the efficacy and safety of merimepodib (MMPD) in combination with remdesivir.
- Target Population: Hospitalized adult patients with confirmed SARS-CoV-2 infection requiring non-invasive ventilation, high flow oxygen devices, or supplemental oxygen.
- Disclaimer: The Company undertakes no obligation to update, supplement, or amend the materials attached to this filing.
Investor Verification Checklist
- Verify the correct registrant name is BioSig Technologies, Inc. (Ticker: BSGM), not Streamex Corp.
- Confirm the date and time of the ViralClear investor call (September 22, 2020, 11:00 AM ET).
- Review the attached press release (Exhibit 99.1) for detailed clinical trial parameters.
- Note that this filing does not contain audited financial data or forward-looking financial guidance.